N/A N=7 Health Services Research

Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS

HIV Infections

Bottom Line

View on ClinicalTrials.gov: NCT05454514 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Mar 2025

Primary outcome: Primary: Rate of Medication Adherence — 2; 1 Participants

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: HiDO medication adherence platform (Device); Automated Medication Platform with Video Observation (Device); Time on Task (Other)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Charles Gellman
Primary completion: May 2023

Outcome Measures

Outcome	Result	p-value
PRIMARY Rate of Medication Adherence	2; 1	—

Summary

This is a 90-day medication adherence study testing the HiDO is an automated AI-driven direct observation medication adherence platform, which is a 510K-exempt, Class I medical device with 24 people with HIV/AIDS, ages 18 to 55, who are currently taking ART and reporting less than 100% adherence. The aims of the study are to see whether the device can achieve >95% ART adherence among all participants averaged over 90 days and to perform usability testing using the System Usability Scale and Net Promoter scores.

Eligibility Criteria

Inclusion Criteria

18-65 years of age
Prescription for at least one existing ART
Has expressed difficulty with medication adherence (question screen)
Access to a personal smart phone and a Wi-Fi connection
Ability to read and write English

Exclusion Criteria

Illicit drug use within the past 6 months (excl. marijuana)
Diagnosis of dementia
Clinical study participation within the previous 3 months
Changes to ART regimen within the previous 2 months
Anticipated change to ART therapy within the study period

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05454514). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.